Autologous bone marrow stromal cells transplantation for the treatment of secondary arm lymphedema
2 views
Skip to first unread message
lymphede...@gmail.com
Oct 26, 2008, 9:59:24 AM10/26/08
to All About Lymphedema
Autologous bone marrow stromal cells transplantation for the treatment
of secondary arm lymphedema: a prospective controlled study in
patients with breast cancer related lymphedema.
Jpn J Clin Oncol. 2008 Oct
Hou C, Wu X, Jin X.
Department of Vascular Surgery, Shandong Provincial Hospital, Shandong
Province, Jinan, China.
OBJECTIVE: To determine the short- and long-term effect of bone marrow
stromal cells (BMSCs) transplantation as a treatment for breast cancer-
related lymphedema. To contrast it with complex decongestive
physiotherapy (CDT).
METHODS: Fifteen women with lymphedema, who had undergone breast
cancer surgery and/no radiotherapy 5 years before, served as the
experimental group and received BMSC transplantation; 35 patients were
measured as the control group treated with CDT. They were kept on
follow-up for 1 year.
RESULTS: Two patients in the CDT Group failed to keep follow-up.
Before treatment, patients had average volume of edema in the affected
arm of 1166.2 ml in BMSC Group and 1091.0 ml in the CDT Group. With
therapy, there was an average decrease in lymphedema volume of 730.7,
887.9 and 958.6 ml in the BMSC Group and 714.8, 657.9 and 571.3 ml in
the CDT Group after 1, 3 and 12 months, respectively. Before
treatment, the percentage of lymphedema was 28.6% in the BMSC Group
and 26.8% in the CDT Group. After treatment, there was a decrease of
64.6, 78.5 and 81.0% in the BMSC Group and 67.2, 60.4 and 54.5% in the
CDT Group after 1, 3 and 12 months, respectively. When asked to
quantify subjectively their pain on a numeric scale from 0 to 5, the
average score of these patients was 3.4 in the BMSC group and 4.0 in
the CDT Group. The average score was reduced to 1.6, 0.8 and 0.6 in
the BMSC Group and to 1.2, 1.7 and 1.6 in CDT Group after 1, 3 and 12
months, respectively.
CONCLUSIONS: Autologous BMSCs transplantation for the treatment of
breast cancer related lymphedema is effective and feasible.
http://jjco.oxfordjournals.org/cgi/content/full/38/10/670
of secondary arm lymphedema: a prospective controlled study in
patients with breast cancer related lymphedema.
Jpn J Clin Oncol. 2008 Oct
Hou C, Wu X, Jin X.
Department of Vascular Surgery, Shandong Provincial Hospital, Shandong
Province, Jinan, China.
OBJECTIVE: To determine the short- and long-term effect of bone marrow
stromal cells (BMSCs) transplantation as a treatment for breast cancer-
related lymphedema. To contrast it with complex decongestive
physiotherapy (CDT).
METHODS: Fifteen women with lymphedema, who had undergone breast
cancer surgery and/no radiotherapy 5 years before, served as the
experimental group and received BMSC transplantation; 35 patients were
measured as the control group treated with CDT. They were kept on
follow-up for 1 year.
RESULTS: Two patients in the CDT Group failed to keep follow-up.
Before treatment, patients had average volume of edema in the affected
arm of 1166.2 ml in BMSC Group and 1091.0 ml in the CDT Group. With
therapy, there was an average decrease in lymphedema volume of 730.7,
887.9 and 958.6 ml in the BMSC Group and 714.8, 657.9 and 571.3 ml in
the CDT Group after 1, 3 and 12 months, respectively. Before
treatment, the percentage of lymphedema was 28.6% in the BMSC Group
and 26.8% in the CDT Group. After treatment, there was a decrease of
64.6, 78.5 and 81.0% in the BMSC Group and 67.2, 60.4 and 54.5% in the
CDT Group after 1, 3 and 12 months, respectively. When asked to
quantify subjectively their pain on a numeric scale from 0 to 5, the
average score of these patients was 3.4 in the BMSC group and 4.0 in
the CDT Group. The average score was reduced to 1.6, 0.8 and 0.6 in
the BMSC Group and to 1.2, 1.7 and 1.6 in CDT Group after 1, 3 and 12
months, respectively.
CONCLUSIONS: Autologous BMSCs transplantation for the treatment of
breast cancer related lymphedema is effective and feasible.
http://jjco.oxfordjournals.org/cgi/content/full/38/10/670
Reply all
Reply to author
Forward
0 new messages